Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H2 2017
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H2 2017
SUMMARY
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) pipeline Target constitutes close to 12 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Prostate Specific Antigen - Pipeline Review, H2 2017, outlays comprehensive information on the Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Prostate-specific antigen (PSA) is a glycoprotein enzyme encoded by the KLK3 gene. PSA is secreted by the epithelial cells of the prostate gland. It is hydrolyzes semenogelin-1 this leads to the liquefaction of the seminal coagulum. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 2, 1 and 4 respectively. Similarly, the universities portfolio in Phase II stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology which include indications Prostate Cancer, Metastatic Hormone Refractory (Castration Resistant and Androgen-Independent) Prostate Cancer.
Furthermore, this report also reviews key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) pipeline Target constitutes close to 12 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Prostate Specific Antigen - Pipeline Review, H2 2017, outlays comprehensive information on the Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Prostate-specific antigen (PSA) is a glycoprotein enzyme encoded by the KLK3 gene. PSA is secreted by the epithelial cells of the prostate gland. It is hydrolyzes semenogelin-1 this leads to the liquefaction of the seminal coagulum. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 2, 1 and 4 respectively. Similarly, the universities portfolio in Phase II stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology which include indications Prostate Cancer, Metastatic Hormone Refractory (Castration Resistant and Androgen-Independent) Prostate Cancer.
Furthermore, this report also reviews key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77)
- The report reviews Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics and enlists all their major and minor projects
- The report assesses Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Overview
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Companies Involved in Therapeutics Development
Advaxis Inc
Aeterna Zentaris Inc
Bavarian Nordic A/S
Inovio Pharmaceuticals Inc
Inspyr Therapeutics Inc
OncBioMune Pharmaceuticals Inc
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Drug Profiles
ADXS-PSA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AEZS-120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target PSA for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-114 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-115 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-5150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody 1 to Inhibit PSA for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonl Antibody to Inhibit PSA for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prostatac - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rilimogene galvacirepvec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Prostate Specific Antigen for Metastatic Hormone Refractory Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Dormant Products
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Discontinued Products
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Product Development Milestones
Featured News & Press Releases
Dec 21, 2017: One-Year Follow-Up Shows 71.4% Progression-Free Survival in 14 Prostate Cancer Patients Treated with ProscaVax in Phase 1 Clinical Trial
Dec 05, 2017: 100% of Prostate Cancer Patients Completing 31-Week Post-Therapy Exam After Treatment with OncBioMune Immunotherapy Show No Disease Progression
Nov 13, 2017: 80% of Prostate Cancer Patients in OncBioMune Phase 1 Clinical Trial of ProscaVax Show No Disease Progression at the First Post-Therapy Follow-up
Sep 19, 2017: Two Abstracts Featuring Advaxis’ Lm-based Candidates Selected for Presentation at the 32nd Annual Society for Immunotherapy Cancer Meeting
Sep 14, 2017: Independent Data Monitoring Committee Recommends Discontinuation of Bavarian Nordic's Phase 3 Study of PROSTVAC in Metastatic Prostate Cancer
Sep 14, 2017: OncBioMune Meets Primary Objective in Trial of ProscaVax Immunotherapy Vaccine for Prostate Cancer
Sep 11, 2017: Principal Investigator Dr. James Gulley to Provide Presentation Entitled 'Therapeutic Vaccines in Prostate Cancer' at the ESMO 2017 Congress
Sep 11, 2017: Inovios Cancer Immunotherapy (INO-5150) Slowed PSA Rise and Significantly Increased PSA Doubling Times In Patients with Recurrent Prostate Cancer
Aug 31, 2017: OncBioMune Awaits Approval from Regulatory Committee to Commence Phase 2 Trial of ProscaVax as Front Line Prostate Cancer Treatment
Aug 29, 2017: OncBioMune to Present Abstract on Clinical Trial of Novel Prostate Cancer Vaccine at American Association of Cancer Research Special Conference
Aug 24, 2017: Final Patient Completes Treatment in OncBioMune Clinical Trial of ProscaVax for Prostate Cancer
Aug 02, 2017: Advaxis to Present at Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
Jul 13, 2017: Phase 2 Trial of ProscaVax for Early-Stage Prostate Cancer Nears Commencement
Jun 27, 2017: Enrollment to Begin in OncBioMunes Trial of ProscaVax for Prostate Cancer in Mexico
Jun 21, 2017: OncBioMune Receives Patent Protecting Novel Cancer Vaccine in Mexico
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Overview
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Companies Involved in Therapeutics Development
Advaxis Inc
Aeterna Zentaris Inc
Bavarian Nordic A/S
Inovio Pharmaceuticals Inc
Inspyr Therapeutics Inc
OncBioMune Pharmaceuticals Inc
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Drug Profiles
ADXS-PSA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AEZS-120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target PSA for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-114 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-115 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-5150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody 1 to Inhibit PSA for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonl Antibody to Inhibit PSA for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prostatac - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rilimogene galvacirepvec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Prostate Specific Antigen for Metastatic Hormone Refractory Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Dormant Products
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Discontinued Products
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Product Development Milestones
Featured News & Press Releases
Dec 21, 2017: One-Year Follow-Up Shows 71.4% Progression-Free Survival in 14 Prostate Cancer Patients Treated with ProscaVax in Phase 1 Clinical Trial
Dec 05, 2017: 100% of Prostate Cancer Patients Completing 31-Week Post-Therapy Exam After Treatment with OncBioMune Immunotherapy Show No Disease Progression
Nov 13, 2017: 80% of Prostate Cancer Patients in OncBioMune Phase 1 Clinical Trial of ProscaVax Show No Disease Progression at the First Post-Therapy Follow-up
Sep 19, 2017: Two Abstracts Featuring Advaxis’ Lm-based Candidates Selected for Presentation at the 32nd Annual Society for Immunotherapy Cancer Meeting
Sep 14, 2017: Independent Data Monitoring Committee Recommends Discontinuation of Bavarian Nordic's Phase 3 Study of PROSTVAC in Metastatic Prostate Cancer
Sep 14, 2017: OncBioMune Meets Primary Objective in Trial of ProscaVax Immunotherapy Vaccine for Prostate Cancer
Sep 11, 2017: Principal Investigator Dr. James Gulley to Provide Presentation Entitled 'Therapeutic Vaccines in Prostate Cancer' at the ESMO 2017 Congress
Sep 11, 2017: Inovios Cancer Immunotherapy (INO-5150) Slowed PSA Rise and Significantly Increased PSA Doubling Times In Patients with Recurrent Prostate Cancer
Aug 31, 2017: OncBioMune Awaits Approval from Regulatory Committee to Commence Phase 2 Trial of ProscaVax as Front Line Prostate Cancer Treatment
Aug 29, 2017: OncBioMune to Present Abstract on Clinical Trial of Novel Prostate Cancer Vaccine at American Association of Cancer Research Special Conference
Aug 24, 2017: Final Patient Completes Treatment in OncBioMune Clinical Trial of ProscaVax for Prostate Cancer
Aug 02, 2017: Advaxis to Present at Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
Jul 13, 2017: Phase 2 Trial of ProscaVax for Early-Stage Prostate Cancer Nears Commencement
Jun 27, 2017: Enrollment to Begin in OncBioMunes Trial of ProscaVax for Prostate Cancer in Mexico
Jun 21, 2017: OncBioMune Receives Patent Protecting Novel Cancer Vaccine in Mexico
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Advaxis Inc, H2 2017
Pipeline by Aeterna Zentaris Inc, H2 2017
Pipeline by Bavarian Nordic A/S, H2 2017
Pipeline by Inovio Pharmaceuticals Inc, H2 2017
Pipeline by Inspyr Therapeutics Inc, H2 2017
Pipeline by OncBioMune Pharmaceuticals Inc, H2 2017
Dormant Projects, H2 2017
Discontinued Products, H2 2017
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Advaxis Inc, H2 2017
Pipeline by Aeterna Zentaris Inc, H2 2017
Pipeline by Bavarian Nordic A/S, H2 2017
Pipeline by Inovio Pharmaceuticals Inc, H2 2017
Pipeline by Inspyr Therapeutics Inc, H2 2017
Pipeline by OncBioMune Pharmaceuticals Inc, H2 2017
Dormant Projects, H2 2017
Discontinued Products, H2 2017
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
COMPANIES MENTIONED
Advaxis Inc
Aeterna Zentaris Inc
Bavarian Nordic A/S
Inovio Pharmaceuticals Inc
Inspyr Therapeutics Inc
OncBioMune Pharmaceuticals Inc
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
COMPANIES MENTIONED
Advaxis Inc
Aeterna Zentaris Inc
Bavarian Nordic A/S
Inovio Pharmaceuticals Inc
Inspyr Therapeutics Inc
OncBioMune Pharmaceuticals Inc
